These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 5658859)
1. Biopharmaceutic equivalency and the role of the Food & Drug Administration. Hodges RM Am J Hosp Pharm; 1968 Mar; 25(3):121-7. PubMed ID: 5658859 [No Abstract] [Full Text] [Related]
2. New York State and drug lists: a history of confusion. Stetler CJ Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687 [No Abstract] [Full Text] [Related]
3. Who really assures prescription drug quality? J Indiana State Med Assoc; 1979 Mar; 72(3):164. PubMed ID: 422862 [No Abstract] [Full Text] [Related]
4. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality? Marsh DA; Hoar ME Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245 [TBL] [Abstract][Full Text] [Related]
5. Drug safety: the viewpoint of the pharmaceutical manufacturing industry. Wigle WW Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099 [No Abstract] [Full Text] [Related]
6. Planning for change. Hansen DC Bull Parenter Drug Assoc; 1969; 23(1):1-5. PubMed ID: 5765717 [No Abstract] [Full Text] [Related]
7. The intensified drug inspection program: procedures and results. Clevenger WL Bull Parenter Drug Assoc; 1969; 23(6):263-8. PubMed ID: 5355888 [No Abstract] [Full Text] [Related]
8. LyphoMed sparks worries. Wagner M Mod Healthc; 1988 Jul; 18(29):5. PubMed ID: 10325202 [No Abstract] [Full Text] [Related]
9. Toward more effective drug regulation. Schmidt AM FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532 [No Abstract] [Full Text] [Related]
10. What's best for the patient? Burkle WS Am J Hosp Pharm; 1983 Apr; 40(4):558. PubMed ID: 6846359 [No Abstract] [Full Text] [Related]
11. FDA inspections of large volume and small volume parenteral manufacturers. Shepherd RE Bull Parenter Drug Assoc; 1976; 30(5):209-13. PubMed ID: 974306 [No Abstract] [Full Text] [Related]
12. The drug efficacy study. Provost GP Am J Hosp Pharm; 1968 Sep; 25(9):483. PubMed ID: 5671558 [No Abstract] [Full Text] [Related]
13. The drug-potency question. Walker JM US Navy Med; 1974 Aug; 64(2):26-30. PubMed ID: 4534296 [No Abstract] [Full Text] [Related]
14. Products in the U.S. pipeline. Pharmaceutical Manufacturers Association. Biotechnology (N Y); 1991 Oct; 9(10):947-9. PubMed ID: 1367805 [No Abstract] [Full Text] [Related]
16. Public standards for drugs: reflections on their use by the professions and industry. Miller LC Hosp Formul; 1976 Mar; 11(3):151-5. PubMed ID: 1026682 [No Abstract] [Full Text] [Related]
17. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. United States Food and Drug Administration's viewpoint. Ley HL; Desmond FH Can Med Assoc J; 1968 Feb; 98(6):318-21. PubMed ID: 5636100 [No Abstract] [Full Text] [Related]
18. Assuring total drug quality. Simmons HE J Am Pharm Assoc; 1973 Feb; 13(2):96-8. PubMed ID: 4686621 [No Abstract] [Full Text] [Related]
19. Securing the US pharmaceutical supply. Somberg JC Am J Ther; 2008; 15(3):197. PubMed ID: 18496255 [No Abstract] [Full Text] [Related]